Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK / Basmah H. ALFAGEH in Journal of Autism and Developmental Disorders, 50-2 (February 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633 Titre : Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK Type de document : Texte imprimé et/ou numérique Auteurs : Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur Article en page(s) : p.625-633 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Incidence  Prevalence  Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 [article] Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK [Texte imprimé et/ou numérique] / Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur . - p.625-633. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633 Mots-clés : Autism spectrum disorder  Incidence  Prevalence  Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416

---

1 (1 - 1 / 1)